WHO WE ARE

WHO WE ARE

Headquartered in New York City, we are committed to raising the standard of care for cancer patients with first-in-class treatments that improve lives and clinical outcomes for millions of patients in need.

Our lead asset, a first-in-class agent, plinabulin is a selective immunomodulating microtubule-binding agent that is being developed as a “pipeline in a drug” in a number of cancer indications:

1. as a direct anti-cancer agent in combination with docetaxel, with positive phase 3 data in NSCLC,
2. in combination with immuno-oncology regimens, as well as
3. prevention of chemotherapy-induced neutropenia (CIN), with positive phase 3 data in combination with G-CSF.

In addition to plinabulin, we have three preclinical immuno-oncology assets and a subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.